Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ)
Weifang, CN
Shandong Wohua Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, production, and distribution of a broad array of medicinal products across the country. The company's extensive product portfolio addresses various therapeutic categories. Key offerings include Xinkeshu tablets, Naoxueshu oral solutions, and Tongluo Huayu capsules, which are specifically formulated for cardiovascular and cerebrovascular health. Beyond these, Shandong Wohua also supplies medications for respiratory conditions, drugs targeting the urinary and digestive systems, anti-rheumatic treatments, and sedative agents. Furthermore, it provides specialized pharmaceuticals tailored for women and children. Headquartered in Weifang, China, the company operates as a subsidiary under the ownership of Beijing Zhongzheng Wanrong Investment (Group) Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.78% | -3.86% | -14.19% | -11.25% | +4.02% | +3.69% | +15.12% | -6.50% | -14.76% | -31.10% | +116.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.0% ★ Q1'26: +0.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+183.3% ★ Q1'26: +50.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+15.8% ★ Q1'26: +8.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.5% Q1'26: +20.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+27.0% ★ Q1'26: +51.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-7.2% ★ Q1'26: +6.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.85% | 599.7K | 0.95% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 10.5K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.7K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 520.3K | 0.06% |
| 5 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 835.97 | 0.22% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.5K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.4K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 596.31 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 68.89 | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 22.64 | 0.31% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ge Zhang | Director & Secretary of The Board | — | male |
| Jiong Wang | CFO, Accounting Supervisor & Director | — | male |
| Qian Yang | Deputy General Manager | — | female |
| Shengting Li | President | — | male |
| Yingzi Zeng | Vice President | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002107.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
